To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.

Welcome to OmegaTown, also known as Newport, Rhode Island. This summer, RB set up camp in the seaside fishing community to put omega-3s to the test.

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

Novo Nordisk is hooking up with new-wave weight loss program Noom to support people with obesity.

Rival PARP inhibitors by GSK and AstraZeneca-Merck already have their own NICE backing, though neither of the three is on routine coverage.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Aurobindo and Glenmark are cited by the FDA. Takeda inks IBD discovery pact with Prometheus. Ascletis recruits Novartis veteran as CSO.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.

As Sanofi CEO Paul Hudson formulates a new strategy for the company, he visited the U.K. for a headquarters opening ceremony.

Merck CEO Ken Frazier knows the industry is in the political "crosshairs," but he cautioned against policies that could "hurt innovation."